Channel Expansion Stilla already leverages partners like Avantor in the United States and Source BioScience in the UK to extend reach. Sales play: identify additional mid-market genomics service providers and CROs in Europe and North America to widen distribution, and propose co marketing with Bio-Rad's customer base post acquisition. Highlight the naica system's easy workflow and high multiplexing as a differentiator.

Oncology Opportunities Opportunity in cancer research and liquid biopsy due to high multiplexing and sensitivity enabling ctDNA detection and gene therapy vector analysis. Focus on labs performing liquid biopsy, oncology research, and companion diagnostic development. Propose bundled offerings of platform access, assays, and development services to accelerate clinical programs.

Integrated Solutions Integration with Niba Labs for assay development and the ability to provide end-to-end solutions including assay development, workflows, and software. Target gene therapy developers and research labs needing rapid assay customization. Offer bundled services, training, and service contracts to secure long term relationships.

Acquisition Upsell Acquisition by a major life sciences company expands potential customer base and cross selling opportunities. Position digital PCR platforms and consumables to the existing installed base, and align with the acquirer's portfolio for complementary workflows. Advocate joint marketing and co selling across regions.

Market Demand Growing demand across infectious disease, wastewater and environmental testing that benefits from highly sensitive and multiplexed digital PCR workflows. Pitch turnkey workflows, reagent kits, and remote support to public health labs, environmental testing labs, and CROs seeking faster and more precise results.